Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease - Full Text View

Purpose

The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.

Condition	Intervention	Phase
Depression	Drug: Fluoxetine	Phase IV

MedlinePlus related topics:

Depression Kidney Failure

Drug Information available for:

Fluoxetine Fluoxetine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Single Group Assignment, Efficacy Study

Official Title:	A 12-Week Open-Label Trial of Once-Weekly Fluoxetine for the Treatment of Depression in Patients With End-Stage Renal Disease

Further study details as provided by Creighton University:

Primary Outcome Measures:

Determine the efficacy and tolerability of once-weekly fluoxetine in aptients with End Stage Renal Disorder who have been diagnosed with depression [ Time Frame: Patients will come in for once weekly visits for 12 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	25
Study Start Date:	February 2007
Estimated Study Completion Date:	August 2008

Intervention Details:

Fluoxetine will be dosed at 90 mg once a week

Detailed Description:

Once-weekly Prozac is a psychiatric medicine, approved by the FDA for the use in treatment of psychiatric disorders. This study will test whether once-weekly Prozac leads to reduced symptoms of depression. Patients requiring dialysis often report symptoms of depression either due to the presence of major depression, a relatively common psychiatric disorder, or due to depression secondary to kidney failure.

Eligibility

Ages Eligible for Study:	19 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of chronic renal failure and end stage renal disease
Ongoing need for regular dialysis treatment
Diagnosis of dperession based on DSMIV
Age tween 19-65 years

Exclusion Criteria:

Inability to provide informed consent
Medically or psychiatrically unstable, as defined by requiring inpatient treatment
Pregnancy, nursing or refusal to use a reliable method of birth control in women
Patients with known allergy to fluoxetine, or previous treatment failure of fluoxetine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00573547

Locations


United States, Nebraska
	Creighton University Department of Psychiatry
	Omaha, Nebraska, United States, 68131
	Creighton Department of Psychiatry
	Omaha, Nebraska, United States, 68131

Sponsors and Collaborators

Creighton University

Investigators


Principal Investigator:	Syed P Sattar, MD	Creighton University Department of Psychiatry

More Information

Responsible Party:	Creighton University ( Syed Pirzada Sattar, M.D. )
Study ID Numbers:	05-13860
First Received:	December 12, 2007
Last Updated:	December 12, 2007
ClinicalTrials.gov Identifier:	NCT00573547
Health Authority:	United States: Institutional Review Board

Keywords provided by Creighton University:

depression

chronic renal failures

end stage renal disease

Study placed in the following topic categories:

Renal Insufficiency

Depression

Kidney Failure, Chronic

Depressive Disorder

Serotonin

Behavioral Symptoms

Fluoxetine

Urologic Diseases

Mental Disorders

Renal Insufficiency, Chronic

Mood Disorders

Kidney Diseases

Kidney Failure

Additional relevant MeSH terms:

Neurotransmitter Agents

Neurotransmitter Uptake Inhibitors

Serotonin Agents

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Physiological Effects of Drugs

Psychotropic Drugs

Antidepressive Agents, Second-Generation

Central Nervous System Agents

Serotonin Uptake Inhibitors

Antidepressive Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008

Sponsored by:	Creighton University
Information provided by:	Creighton University
ClinicalTrials.gov Identifier:	NCT00573547